Medical weight loss is obesity treatment overseen by a licensed clinician, typically a prescription drug plus eating and activity support and regular check-ins.
Tirzepatide for Minneapolis patients
Zepbound, Lilly's tirzepatide brand, carries two labeled uses: long-term weight management, and obstructive sleep apnea in adults who have obesity [6]. A Minneapolis buyer paying LillyDirect directly spends $299 on 2.5 mg, $399 on 5 mg and $449 on any strength from 7.5 to 15 mg, as long as refills land within 45 days [2]. Kept up for twelve months at the top tier, that is $5,388, or roughly 6.7% of the city's $80,846 median household income [5]. SURMOUNT-1 participants on 15 mg averaged a 20.9% loss of body weight by week 72 [7]; our Zepbound results page explains what that average hides.
Sponsored placement: open.
One local practice can be featured here. This is a paid, labeled placement and never an endorsement.
Feature your practice in Minneapolis, from $300 a month.
Sponsored listing, labeled. It is not a ranking or an endorsement. Practices can visit sponsor a city.
A state that still pays through Medicaid
Stateline's April 2026 report, drawing on KFF, put Minnesota on the short list of states whose Medicaid programs pay for obesity GLP-1s [1]; KFF's January count of such states was 13 [8]. Ask your Medical Assistance plan which brand it prefers and what paperwork it wants. Only 11.4% of Minneapolis residents are 65 or older [5], but those on Part D can look at the Medicare GLP-1 Bridge: $50 a month for Wegovy, Foundayo or a Zepbound KwikPen if they meet its rules [9] [10]. More on GLP-1 coverage and Medicare.
Lilly and Novo cash prices
| Medicine | How taken | Monthly | Ref |
|---|---|---|---|
| Foundayo | Tablet, once a day | $149 to $299 | [3] |
| Wegovy | Tablet, once a day | $149 to $299 | [11] |
| Wegovy | Pen, once a week | $349 | [11] |
| Zepbound | Vial or KwikPen, once a week | $299 to $449 | [2] |
Hennepin County data and local checks
CDC PLACES places Hennepin County's adult obesity rate at 27.1% and its diabetes rate at 8.1%; inside Minneapolis the model reads 28.6% and 7.4% [4] [12]. We were unable to confirm a local hospital weight program and its price this month, so none is named. Your primary care clinic is the first call. The Minnesota Board of Medical Practice is where a prescriber's license can be confirmed [13].
Minnesota law adds a referral rule: Minn. Stat. 147.091 lets the board discipline a physician who takes a commission or rebate mainly for referring patients or for prescribing a drug [17]. A clinic paying influencers per signup deserves a second look. Then compare tirzepatide online and the clinic checklist.
Other Midwest guides: Kansas City, Chicago, Detroit. Also semaglutide in Minneapolis and the weight loss hub.
About compounded tirzepatide
No compounded tirzepatide has FDA approval, and FDA does not check these products for safety, effectiveness or quality. By May 31, 2026, FDA had logged more than 730 adverse event reports tied to compounded tirzepatide [14]. The period when pharmacies could routinely compound tirzepatide copies ended March 5, 2025 [15].
Zepbound label points
In rats, tirzepatide caused thyroid C-cell tumors, so Zepbound has a boxed warning and must not be used by anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 [16]. Seek care for stomach pain that is severe and persistent, for signs of an allergic reaction, or for lows if insulin or a sulfonylurea is also in the mix. Stop when pregnancy is recognized. Emergencies: 911.
Questions people ask
What does tirzepatide cost in Minneapolis without insurance?
On Oct 17, 2026, LillyDirect sold Zepbound for $299 to $449 a month, the price rising with the dose [2].
Does Minnesota Medical Assistance pay for weight-loss GLP-1s?
Stateline, citing KFF, listed Minnesota's Medicaid program among those covering GLP-1s for obesity in 2026 [1]. Your plan decides which brand and what proof of need.
How common is obesity in Hennepin County and Minneapolis?
Which GLP-1 has the lowest cash price for a Minneapolis buyer?
Can a Minnesota doctor take payments for referring weight loss patients?
Minn. Stat. 147.091 makes taking a commission or rebate primarily for patient referrals, or for prescribing drugs, grounds for board discipline [17].
Will the Medicare Bridge cover a Zepbound vial?
No. The Bridge pays only for the Zepbound KwikPen, not the single-dose vial [10].
Sources
17 cited
- More states consider dropping GLP-1 weight loss drugs from Medicaid. Stateline (States Newsroom), Apr 30, 2026.
- Zepbound self-pay prices on LillyDirect. Eli Lilly and Company (LillyDirect), Oct 17, 2026.
- Foundayo self-pay prices on LillyDirect. Eli Lilly and Company (LillyDirect), Oct 17, 2026.
- PLACES county data, 2025 release: Hennepin County, MN. Centers for Disease Control and Prevention, 2025 release (2023 BRFSS).
- QuickFacts: Minneapolis city, Minnesota. U.S. Census Bureau, 2025 estimates and 2020-2024 ACS; accessed 2026-10-17.
- Zepbound label. DailyMed, National Library of Medicine, Aug 2026.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine (PubMed), 2022.
- Medicaid coverage of and spending on GLP-1s. KFF, Jan 16, 2026.
- Weight loss drugs coverage (Medicare GLP-1 Bridge). Medicare.gov (CMS), Oct 17, 2026.
- Medicare GLP-1 Bridge: information for pharmacies. Centers for Medicare & Medicaid Services, Oct 17, 2026.
- Wegovy self-pay offer, NovoCare Pharmacy. Novo Nordisk (NovoCare), Oct 17, 2026.
- PLACES place data, 2025 release: Minneapolis, MN. Centers for Disease Control and Prevention, 2025 release (2023 BRFSS).
- Contact a state medical board. Federation of State Medical Boards, Oct 17, 2026.
- FDA's concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration, Oct 1, 2026.
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. U.S. Food and Drug Administration, Apr 1, 2026.
- Zepbound (tirzepatide) prescribing information. U.S. Food and Drug Administration, Apr 2026.
- Minnesota Statutes 147.091. Minnesota Office of the Revisor of Statutes, accessed 2026-10-17.
This page is general information, not medical advice. Talk with a licensed clinician about your own care.